Version 1
: Received: 9 October 2023 / Approved: 10 October 2023 / Online: 10 October 2023 (09:55:19 CEST)
How to cite:
Tandon, A.; Nagalla, D. From Transcription Factors to Personalized Vaccines: A Multifaceted Review of Glioblastoma Research and Treatment. Preprints2023, 2023100607. https://doi.org/10.20944/preprints202310.0607.v1
Tandon, A.; Nagalla, D. From Transcription Factors to Personalized Vaccines: A Multifaceted Review of Glioblastoma Research and Treatment. Preprints 2023, 2023100607. https://doi.org/10.20944/preprints202310.0607.v1
Tandon, A.; Nagalla, D. From Transcription Factors to Personalized Vaccines: A Multifaceted Review of Glioblastoma Research and Treatment. Preprints2023, 2023100607. https://doi.org/10.20944/preprints202310.0607.v1
APA Style
Tandon, A., & Nagalla, D. (2023). From Transcription Factors to Personalized Vaccines: A Multifaceted Review of Glioblastoma Research and Treatment. Preprints. https://doi.org/10.20944/preprints202310.0607.v1
Chicago/Turabian Style
Tandon, A. and Deepthi Nagalla. 2023 "From Transcription Factors to Personalized Vaccines: A Multifaceted Review of Glioblastoma Research and Treatment" Preprints. https://doi.org/10.20944/preprints202310.0607.v1
Abstract
Glioblastoma (GBM) is one of the most aggressive and intricate forms of brain cancer, demanding novel therapeutic interventions. The role of transcription factors in epigenetic regulation has emerged as a promising avenue for targeting GBM. This comprehensive review seeks to explore the complex interplay between specific transcription factors such as SNAI2, FOXA1, YAP1, TWIST1, ZEB1, and NF-kB, and their role in GBM progression and therapy. The focus extends to innovative therapeutic strategies, including epigenetic modifiers, targeted therapies, and CRISPR/Cas9 technology. A unique aspect of this review highlights the connection between transcription factors, neoantigen presentation, and personalized immunotherapy in GBM. By delving into current research, clinical trials, and immunological data, this review emphasizes the significant potential of targeting transcription factors for personalized immunotherapy in GBM. The challenges, future perspectives, and ethical considerations are also critically discussed, offering a complete and thought-provoking insight into a vital and rapidly evolving field.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
